See more : Manpasand Beverages Limited (MANPASAND.NS) Income Statement Analysis – Financial Results
Complete financial analysis of VBI (4170.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VBI, a leading company in the Biotechnology industry within the Healthcare sector.
- Reconnaissance Energy Africa Ltd. (RECWF) Income Statement Analysis – Financial Results
- Checkmate Pharmaceuticals, Inc. (CMPI) Income Statement Analysis – Financial Results
- Julius Bär Gruppe AG (0QO6.L) Income Statement Analysis – Financial Results
- Refined Metals Corp. (RMC.CN) Income Statement Analysis – Financial Results
- Tgi Infrastructures Ltd (TGI.TA) Income Statement Analysis – Financial Results
VBI (4170.TWO)
About VBI
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It offers cell preparation product manufacturing; and collection, processing, and storage management of immune cells. The company's cell preparation products are used in the field of infectious diseases and inflammation, cancer, and tumor diseases. Vectorite Biomedical Inc. was founded in 1993 and is based in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 55.85M | 42.91M | 28.77M | 24.54M | 26.54M |
| Cost of Revenue | 39.43M | 42.21M | 31.24M | 22.63M | 23.72M |
| Gross Profit | 16.42M | 707.00K | -2.47M | 1.92M | 2.83M |
| Gross Profit Ratio | 29.40% | 1.65% | -8.60% | 7.81% | 10.64% |
| Research & Development | 6.59M | 5.43M | 13.25M | 25.63M | 45.00M |
| General & Administrative | 22.62M | 22.37M | 20.78M | 27.41M | 25.05M |
| Selling & Marketing | 3.34M | 3.45M | 5.91M | 9.81M | 15.25M |
| SG&A | 25.96M | 25.82M | 26.69M | 37.22M | 40.31M |
| Other Expenses | 0.00 | 3.20M | 55.73M | 0.00 | -4.75M |
| Operating Expenses | 32.56M | 31.24M | 39.93M | 73.21M | 85.15M |
| Cost & Expenses | 71.99M | 73.45M | 71.18M | 95.84M | 108.87M |
| Interest Income | 3.55M | 1.97M | 866.00K | 394.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 108.00K |
| Depreciation & Amortization | 9.16M | 8.86M | 16.51M | 18.21M | 19.86M |
| EBITDA | -6.97M | -21.68M | -25.94M | -42.72M | -67.47M |
| EBITDA Ratio | -12.48% | -48.24% | -89.97% | -174.06% | -300.36% |
| Operating Income | -16.13M | -29.56M | -42.39M | -60.93M | -99.58M |
| Operating Income Ratio | -28.88% | -68.88% | -147.34% | -248.24% | -375.19% |
| Total Other Income/Expenses | 9.50M | 4.08M | 50.76M | -10.76M | -17.61M |
| Income Before Tax | -6.63M | -26.45M | 8.33M | -71.69M | -99.94M |
| Income Before Tax Ratio | -11.87% | -61.64% | 28.95% | -292.09% | -376.53% |
| Income Tax Expense | 0.00 | -41.00K | -29.00K | -3.52M | -9.67M |
| Net Income | -6.60M | -26.41M | 8.36M | -68.17M | -90.27M |
| Net Income Ratio | -11.82% | -61.55% | 29.05% | -277.75% | -340.11% |
| EPS | -0.15 | -0.60 | 0.12 | -2.34 | -2.14 |
| EPS Diluted | -0.15 | -0.60 | 0.12 | -2.33 | -2.14 |
| Weighted Avg Shares Out | 43.77M | 43.77M | 69.65M | 29.13M | 42.14M |
| Weighted Avg Shares Out (Dil) | 43.77M | 43.77M | 69.65M | 29.23M | 42.14M |
Source: https://incomestatements.info
Category: Stock Reports